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ABSTRACT 
Long-term outcomes in multiple sclerosis (MS) are highly varied and treatment with disease-modifying 
therapies carries significant risks. Finding tissue biomarkers that can predict clinical outcomes would be 
valuable in individualising treatment decisions for people with MS. Several candidate biomarkers—reflecting 
inflammation, neurodegeneration and glial pathophysiology—show promise for predicting outcomes. 
However, many candidates still require validation in cohorts with long-term follow-up and evaluation for their 
independent contribution in predicting outcome when models are adjusted for known demographic, clinical 
and radiological predictors. Given the complexity of MS pathophysiology, heterogeneous panels comprising a 
combination of biomarkers that encompass the various aspects of neurodegenerative, glial and immune 
pathology seen in MS, may enhance future predictions of outcome. 
INTRODUCTION 
Multiple sclerosis (MS) is a common cause of neurological disability in young adults. The diagnosis can usually 
be made with a high degree of accuracy,1 but clinical outcomes in MS are very varied. Disease-modifying 
therapies (DMTs) hold promise for improving long-term outcomes, but also carry significant risks. 
Individualised MS treatment relies heavily on the availability of robust predictors of prognosis, an area where 
tissue biomarkers may add value. 
Biomarkers are characteristics that are objectively measured and evaluated as indicators of normal biological 
processes, pathogenic processes or pharmacological responses to a therapeutic intervention.2 The availability 
of a biomarker that reliably predicts outcomes in MS would allow clinicians to counsel patients more 
effectively, guide treatment decisions and also influence patient selection for clinical trials. Several markers of 
MS outcome have emerged from clinical practice, for example, T2-hyperintense brain/spinal cord MRI lesions 
predicting conversion from clinically isolated syndrome (CIS) to MS, or the use of anti-JC virus antibody index 
to predict risk of progressive multifocal leukoencephalopathy on natalizumab. However, a more recent 
targeted, screening approach is being widely applied to the discovery of tissue biomarkers for MS and other 
neurological diseases. This has generated hundreds of publications proposing candidate markers but it is often 
unclear how valid and robust these biomarkers are and how they should be applied in clinical practice. 
In 2001, the National Institutes of Health Biomarkers Definition Working Group working group published 
consensus guidelines on the terminology and potential roles of biomarkers (table 1). However, although the 
Food and Drug Administration and European Medicines Agency have rigorous processes for licensing 
medications, their mechanisms for validating biomarkers are less standardised, and few biomarkers ever gain 
their formal approval. 
Here, we report the current status of prognostic tissue biomarkers in MS. The role of imaging markers and 
some other biomarker types (table 2) are well summarised elsewhere.3 4 
CANDIDATE TISSUE BIOMARKERS MS is fundamentally considered to be an autoimmune disorder of the central 
nervous system (CNS). While T-cells have long been considered central to its pathophysiology, there is a 
growing appreciation of the important role of B-cells and the glial compartment in MS pathogenesis. 
Neuroaxonal pathology is now well recognised in MS and is thought to be largely responsible for long-term 
disability. Genome-wide association studies have identified numerous variants that confer a modest increase 
in the risk of MS, while observational studies have highlighted the relevance of environmental factors such as 
smoking, Epstein–Barr virus infection, vitamin D status and obesity. This knowledge has influenced the search 
for candidate biomarkers of outcome. 
 
Taken from the BEST produced in 2015. 
BEST, Biomarkers, Endpoints, and other Tools; FDA, Food and Drug Administration; NIH, National Institutes of 
Health. 
 
 
 
MARKERS OF INFLAMMATION 
Oligoclonal bands/Free light chains 
Oligoclonal bands (OCBs) are bands of immunoglobulin (usually IgG), produced by clonal plasma cells. The 
presence of two or more bands incerebrospinal fluid (CSF), but not serum, provides evidence of an intrathecal 
humoral immune response. The identification of CSF-specific OCBs has recently been adopted as a 
confirmatory criterion for the diagnosis of MS in people with a CIS plus MRI evidence of dissemination in 
space.1 However, OCBs also provide prognostic information. A meta-analysis of 12 253 people with MS 
reported the prevalence of CSF-specific OCBs at 87.7%.5 CSF-specific OCBs detected using isoelectric focusing 
(the gold standard) in 1918 people with MS were associated with an OR of 1.96 for reaching a disability 
outcome (Expanded Disability Status Scale [EDSS] 4 at 10 years, EDSS 6 during follow-up or increase of ≥1 EDSS 
point in 5 years).5 Likewise, Joseph et al found that OCB-negative status was associated with a HR of 0.65 
(p=0.06) for reaching EDSS 4 and 0.52 (p=0.04) for reaching EDSS 6 (mean follow-up 72 months, adjusted for 
age, clinical presentation and baseline MRI findings).6 Tintore et al also reported that in 792 people with CIS, 
OCB-positive status was associated with a HR of 2.0 (95%CI1.2 to 3.6) for reaching EDSS 3 (mean follow-up 6.8 
years, adjusted for known clinicoradiological predictors of outcome).7 
Immunoglobulin-free light chains (FLC) are produced in excess during intrathecal immunoglobulin production 
and circulate in the CSF. The presence of CSF kappa and lambda free light chains (k-FLC and λ-FLC) is 
recognised in MS.8 CSF k-FLC may rival OCBs in diagnostic accuracy for MS,9 10 and may also offer modest 
prognostic information. In an early study, Rudick et al found CSF k-FLC in the upper quartile of the range to be 
a predictor of 36 month EDSS in 36 people with MS (HR 3.78, p=0.04).11 Makshakov et al reported that in 98 
people with CIS who subsequently converted to MS, k-FLC concentration at the time of first attack correlated 
with EDSS at 2 years (r=0.45, p=0.0016).9 Rinker et al also found CSF k-FLC concentrations above 1.53 micg/mL 
predicted the need for ambulatory assistance in 57 people with MS when followed for a median of 15 years 
(specificity 87.5%, positive predictive value 88.9%).12 While Voortman et al found no correlation between 
baseline CSF k-FLC and subsequent EDSS progression or relapse rate in 61 people with CIS or MS, by 4.8 years 
only 36 (59%) had converted to MS and most (61%) had received DMTs.13 More recently, Rath-bone et al 
suggested that the ratio of k:λ FLC may be more predictive than either in isolation. They found a CSF k:λ FLC 
ratio <9 at diagnostic lumbar puncture was moderately predictive of an EDSS >3 at 5 years in people with 
CIS/MS (75% sensitivity and 57.1%specificity).14 
 
Inflammatory cytokines 
C-X-C motif chemokine 13 (CXCL13) is a potent B-cell activating chemokine, important in recruiting 
lymphocytes to sites of inflammation. Khademi et al found significantly higher CSF CXCL13 concentrations in 
people who had experienced a high cumulative number of MS relapses over their disease course (n=323), and 
that baseline CSF CXCL13 concentration was highest in those who went on to have over four relapses in the 
subsequent 5 years (n=52). They found no significant association between CSF CXCL13 levels and EDSS.15 
Alvarez et al reported a significant correlation between CSF CXCL13 and EDSS but this was in a small group of 
people with either neuromyelitis optica (n=9) or MS (n=9), and the effect may have been driven by high EDSS 
grades in neuromyelitis optica.16 Novakova et al found no relationship between CSF CXCL13 and either relapse 
rate or EDSS in 59 people with MS.17 
CSF CXCL13 also shows a treatment response in MS. One group has shown that the magnitude of reduction in 
CSF CXCL13 is greater in those who receive immune-modulating treatment than those who receive placebo.18 
Alvarez et al found that a higher CSF CXCL13 concentration at baseline was associated with response to 
rituximab (defined as no evidence of disease activity, NEDA) in 30 people with MS, and observed reductions in 
CSF CXCL13 after treat-ment.19 However, some of these studies also highlight the lack of specificity offered by 
CSF CXCL13, which can be significantly elevated in people with other neuroinflammatory disorders and CNS 
infections.15 16 
 
MARKERS OF NEURODEGENERATION 
Neuronal proteins are promising biomarkers in MS. The most studied of this subgroup are the neurofilaments, 
comprising neurofilament heavy, medium and light chains and αinternexin. These proteins contribute to the 
neuronal cytoskeleton and allow radial cell growth. Increased concentration in CSF and serum provides 
evidence of CNS axonal damage. The relatively short half-life of neurofilament light (NfL) compared with the 
more extensively phosphorylated heavy chains suggests that levels are more likely to reflect recent axonal 
damage. 
NfL has become one of the most widely studied prognostic biomarkers in MS. Most early work was performed 
on CSF-NfL; the low sensitivity of ELISA techniques was previously a major barrier to using serum NfL as a 
prognostic biomarker. However, a novel single-molecule array technique (SiMoA) is now available to measure 
NfL in the serum.20 SiMoA appears sensitive and shows strong correlations between CSF-NfL and serum-NfL 
(sNfL) concentrations suggesting promise for a less invasive method of prognostic testing.21–23 
Numerous studies have shown that CSF-NfL rises at the time of clinical relapse,17 24–26 a finding that has also 
been reproduced using sNfL.21–23 CSF-NfL appears to remain elevated for 2–3 months after relapse before 
returning to baseline.27 There have been no consistent correlations between either serum or CSF-NfL and 
concurrent disability. Correlations tend to be imperceptible in small cohorts,17 23 26 28 lost in multivariate 
analyses by the addition of clinicodemographic covari-ates,29 or associated with relatively modest effect sizes 
in larger cohorts.21 22 27 
Starting a DMT is often associated with a fall in CSF-NfL,17 25 26 28 30 and sNfL.21–23 However, it is diff-cult 
to exclude regression to the mean in many of these studies given that patients often start DMT in response to 
a recent relapse. 
Several studies have validated the prediction of future disability using CSF-NfL but the effect sizes are modest. 
In one of the earliest studies, Lycke et al found that CSF-NfL at baseline predicted annualised relapse rate at 2 
years in 60 people with treatment-naïve relapsing-MS (r2=0.38, p<0.01).27 Selleberg et al found that twofold 
higher baseline CSF-NfL was associated with a HR of 1.17 for relapse at 2 years (95% CI1.01 to 1.36), but with 
no association between base-line CSF-NfL and conversion to secondary progresive (SP) MS or change in EDSS 
at 5 years.31 Bhan et al showed that for 35 people with relapsing-remit-ting MS at baseline, conversion to 
SPMS at 5 years was associated with a significantly higher median baseline CSF-NfL but with wide variation 
(2122 ng/L (IQR1921 ng/L) vs246 ng/L (IQR 885 ng/L), p=0.01).32 In a small cohort of people with progressive 
MS, Trentini et al found CSF-NfL significantly predicted EDSS progression over 9 years of follow-up, ( 0.44, 
R2=0.195, p=0.025).33 Salzer et al found that CSF-NfL at diagnostic lumbar puncture in 89 people with MS 
correlated with MS severity scale (MSSS) after median 14 years of follow-up (r=0.3, p=0.005), and that baseline 
CSF-NfL >386 ng/L was associated with a higher risk of severe MS (MSSS above median) at 14 years (OR 5.2, 
95% CI1.8 to 15).34 
Serum NfL has also been validated in some studies to exert modest predictions of MS outcomes. Disanto et al 
found baseline sNfL predicted an increased risk of relapse in the subsequent 12 months in an unadjusted 
analysis in 388 people with CIS/MS (HR 1.94 (95% CI1.21 to 3.10), p=0.006). Risk of EDSS worsening in the 12 
months after blood sampling was higher in people with sNfL>97.5th percentile (appropriate for age) versus 
those with sNfL<80th percentile (15% vs 6.7%; OR 2.41, (95% CI1.07 to 5.42)p=0.03).22 Barro et al found that 
sNfL>90th percentile predicted EDSS worsening in the next 12 months, in a multivariate model adjusting for 
other predictors of outcome including baseline T2 lesion load in 259 people with MS (OR 2.786 (95% CI1.609 to 
4.826) p<0.001).35 sNfL does not predict medium-term or long-term outcomes in MS. Piehl et al. (n=243) and 
Kuhle et al. (n=42) found no associations between baseline sNfL and 2 year outcomes.23 36 Chitnis et al also 
found no relationship between sNfL and 10-year disability outcomes (n=122).37 
There are no universally agreed clinically relevant cut-off values for CSF and serum NfL. Some authors have 
used the median value in their cohort, whereas others have expressed NfL concentrations relative to age-
matched controls. One study found that CSF-NfL above 450 ng/L was associated with a sensitivity of 81% and 
specificity of 57% for disease activity at 4 years,38 and CSF NfL above the median expected value in an age-
matched control was associated with 67% sensitivity and 75% specificity for disease activity at 12 months.21 
Another study modelled outcomes based on CSF-NfL, adjusting for age, disease duration and sex. Each 1000 
ng/L increment in baseline CSF-NfL predicted a 0.47 increase in EDSS at 5 years (95% CI0.25 to 0.69).32 
Likewise, in the same two studies, sNfL above 14.2 ng/L provided a sensitivity of 72% and specificity of 57% for 
disease activity (modified NEDA) at 4 years,38 and sNfL above 18.2 ng/L was associated with 45% sensitivity 
and 80% specificity for disease activity at 12 months.21 
In summary, CSF-NfL appears to be of some help in predicting short-term and long-term outcomes in MS, 
while sNfL is more useful for predicting short-term outcomes. However, the effect sizes are modest and 
confidence intervals are wide. 
Neurofilament heavy (NfH) in the CSF has been shown in several studies to be a surrogate marker of current 
ability but with no established utility as a predictor of outcome.33 39–41Neurofilament medium and α-
internexin have been studied in less detail in MS, in part related to difficulties in their analysis. 
 
GLIAL MARKERS 
Astroglial activation is associated with activation of the immune cascade and is thought to play a role in the 
demyelination and neuroaxonal injury observed in MS.42Glial fibrillar acidic protein (GFAP) is the major 
constituent of gliotic scarring. CSF-GFAP correlates modestly with EDSS in cross-sectional analyses,43–45 and 
baseline CSF-GFAP appears modestly predictive of long-term clinical outcomes. Axelsson et al found baseline 
CSF-GFAP predicted EDSS score at 8–10 years (r=0.45, p<0.05).43 Martinez et al found that baseline CSF-GFAP 
predicted time to EDSS 3 (HR 1.83[95% CI1.01 to 3.35],p=0.04).42 Encouragingly, Abdelhak et al recently 
reported using SiMoA technology to measure serum GFAP in MS and found that after correction for age, 
serum GFAP concentrations modestly correlated with EDSS in progressive MS (r=0.4, p=0.008).46 
Chitinase-like proteins (YKL-40), expressed by astrocytes in the CNS, is thought to play a role in chronic 
inflammation in MS via regulation of the innate immune system.47 Modvig et al found baseline CSF-CHI3L1 
predicted cognitive impairment at 13.6 years (mean) in 34 people with MS (r=0.41, p=0.015).48 Martinez at al. 
found CHI3L1 was the best predictor of disability progression in a multivariate analysis of several CSF 
biomarkers. CHI3L1 predicted time to EDSS 3 (HR 2.78[95% CI1.48 to 5.23],p=0.001) and time to EDSS 6 (HR 
5.7[95% CI1.01 to 20.83],p=0.05).42 Canto et al found CSF-CHI3L1 to be the only significant independent risk 
factor for reaching EDSS 3 (HR=3.82; p=5.3×10−8) in 813 people with CIS or MS, in a multi-variate analysis 
including baseline MRI and OCB status. CSF-CHI3L1 levels>170 ng/mL were associated with 74% sensitivity and 
60% specificity of reaching EDSS 3 at (mean) 5.4 years.49   
 
CLINICAL USE OF CANDIDATE BIOMARKERS IN MS 
There is a long list of candidate biomarkers that differ in expression between people with MS and healthy 
controls but require validation for prognostic utility (figure 1). There are several features to consider regarding 
possible prognostic biomarkers in the clinic (table 3). 
First,the in vitro test of a biomarker requires laboratory validation for its sensitivity, reproducibility, 
repeatability and standardisation in relation to reference materials. An inappropriate assay could lead to false 
negative results as is likely in studies using older versions of sNfL assay.36Second, analytical validation requires 
a disease cohort to measure the sensitivity and specificity of the marker for relevant outcomes. It is important 
to distinguish markers that correlate with and markers that predict outcome. There is no universal agreement 
on the optimum clinical outcome measure for prognostic biomarkers in MS. Many groups have explored the 
prediction of disease activity (eg, relapses) in the subsequent 12–24 months, which would provide a rationale 
for influencing short-term treatment decisions. Others argue that an ideal MS biomarker would predict 
disability status after 10–20 years. However, this approach has some limitations, such as the known 
inadequacies of MS disability rating scales, which may undermine the ability to demonstrate the predictive 
performance of a biomarker,for example, baseline sNfL correlates with 10-year brain volume but not 10-year 
disability.37 Further-more, the widespread and often heterogeneous use of DMTs in any MS cohort prohibits 
the study of the prediction of long-term outcomes. Almost all of the studies aimed at validating the utility of 
NfL as a biomarker used cohorts with DMT exposure rates exceeding 40%.17 21–23 25 26 28 30 32 34 35 37 38 
 
 
 
 
 
 
After analytical validation, candidate biomarkers require clinical validation in independent large clinical cohorts 
from different centres. Clinical validation should also evaluate a biomarker’s independent contribution in 
predicting outcome when models are adjusted for known demographic, clinical and radiological prognostic 
factors. A minority of studies have incorporated candidate biomarkers into multivariate models adjusting for 
known demographic, clinical and radiological predictors of outcome.35 50 Furthermore, several studies have 
highlighted the lack of specificity of several candidate biomarkers, which may give confounding effects of, for 
example, coexistent neurological disease, concurrent systemic illness, acute trauma or age. Before a candidate 
could be adopted into routine clinical use, a reference range is required, including age-adjustment where 
relevant for example, in the case of NfL.22 35 
 
THE FUTURE OF MS PREDICTIVE BIOMARKERS  
None of the existing tissue biomarkers of MS prognosis appear ready for widespread clinical use. Given the 
gaps in the current data, identifying markers that will most likely help with clinical prognosis remains 
speculative. Given the complexity of MS pathophysiology, we probably need panels comprising a combination 
of markers. Other advances include the ability of screening technologies to profile a person’s gene expression, 
cytokine transcription, T-cell receptors, autoantibody repertoire, microRNA expression or the microvesicle 
contents, providing a unique signature that may better predict outcome or treatment response. 
There are clear advantages in the convenience of a serum biomarker, avoiding the need for lumbar puncture. 
However, the utility of serum biomarkers will inevitably depend on the extent to which the CNS pathology in 
MS is reflected by changes in the blood. There is likely to be a trade-off between the convenience of obtaining 
samples and their disease relevance; the most valuable biomarkers may be derived from the disease-relevant 
cell populations in the CNS. 
 
 
 
 
CONCLUSION 
Clinical outcomes in MS are highly varied and existing prognostic variables are of limited value in predicting 
outcome for an individual. Tissue biomarkers show promise for improving the prediction of outcome in MS and 
may also offer additional value in diagnosis and monitoring. While some candidate markers show considerable 
promise, most are not disease-specific and may require adjustment for confounding effects of age and/or 
comorbidity. In the context of a disease with complex pathophysiology, it may be best in the future to develop 
heterogeneous panels of biomarkers that encompass the various aspects of neurodegenerative, glial and 
immune pathology seen in MS. 
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